Juniper Publishers- Linked In

Juniper Publishers- Linked In

To advance the creation, communication and application of scientific knowledge to benefit society and improve people's lives. The prime mission of juniper is to make continuous efforts in transforming the scientific information from people around the world by publishing in our website. Our vision is to build an open science platform where everybody has equal opportunity to seek, share and generate knowledge, and that empowers researchers in their daily work.

Juniper publishers are established with the main motto of spreading the scientific information to the whole research community throughout the universe. We as an Open Access publishers are on the way to reach the peaks of the provision in scientific publications through on-line. With Open Access process, we take away all the barriers that ancient publication models had. To match with the rapidity of the twenty first century, and thus to stand as a large international analysis of the research works. We assure all readers about the valuable circulation of recent advancements and research methods to the whole scientific community. Juniper Publishers is a platform for professors and researchers who have the determination to post the quality information in the website thereby giving out their helping hands to the scholars/researchers in their field of interest. We are dedicated to work in the division of science, engineering and further more research areas.

Juniper publishers are glad to initiate the perception of membership to promote the scientific community. We offer different types of memberships for research scholars, scientists, professors, authors, reviewers, editors and students. Funds received from the membership will cover the Article Processing Fee and Grants, Financial Aid to young scholars and researchers. Juniper Membership is introduced to help the authors (who submit the articles often) to get rid of article processing charges & to provide more benefits.


To Read More about Juniper PublishersLinkedIn Click on: https://in.linkedin.com/company/juniper-publishers
To Know More about Juniper Publishers click on: https://juniperpublishers.com/
For More Open Access Journals in Juniper Publishers Click on: https://juniperpublishers.com/journals.php


Comments

Post a Comment

Popular posts from this blog

Juniper Publishers| The Anatomical Architecture of the Junction between the Great Cerebral Vein and the Straight Sinus in Correlation to the Physiological and Biochemical Impact on Multiple Sclerosis Subtypes and Disease Progression- A Review Article

Image
  Journal of Surgery -  JuniperPublishers Abstract Introduction:  Multiple Sclerosis (MS) is a debilitating autoimmune disorder, characterized by damage to the white matter of the central nervous system. Studies suggest a relationship between impaired cerebral venous blood flow and progressive destruction of white matter in the CNS. Altered cerebral venous architecture is a possible mechanism that may contribute to a compromised venous blood flow pattern in MS patients. Natural variations at junction located between the great cerebral vein (GCV) and the straight sinus (Ss) located within the cerebral venous drainage system can potentially exacerbate MS progression. Recent data indicates that abnormal cerebral venous hemodynamics contributes to the pathophysiology observed in MS through an unknown mechanism that increases hydraulic resistance. Objective:  This review aims to investigate if anatomical variations at the GSV and Ss junction elicit a profound effect on the cerebral venous s
Read more

Juniper Publishers| The Use of the Second-Generation Protein Kinase Inhibitors in Patients with Gastrointestinal Stromal Tumor with Failure to the Treatment with Imatinib

  Journal of Surgery -  JuniperPublishers Introduction:  Gastrointestinal Stromal Tumor (GIST) is considered the most common mesenchymal tumor of the gastrointestinal tract. Approximately 85% of GISTs have mutations in proto-oncogene KIT encoding, a tyrosine kinase receptor. About 8% of GISTs are associated to mutations in the growth factor receptor alpha (PDGFRA) gene. The standard treatment of GIST is the surgical resection of the tumor. In cases of metastasis and tumor recurrence specific drugs as tyrosine kinase inhibitors are used. The first line treatment is Imatinib. Although the treatment with imatinib failed in some patients for the metastatic and relapsed treatment of GIST, the patients can to use other drugs, called second generation. Discussion:  One of the great advances in the diagnosis of GIST was the recognition through the immunohistochemistry of the c-Kit marker. The tyrosine kinase inhibitor, imatinib, has become the standard treatment for those, with high-risk resec
Read more